Description
Glialia 700 (Syrup, 200 ml)
Glialia 700 is an ultramicronized oral suspension containing palmitoylethanolamide (PEA) 700 mg plus luteolin 70 mg in 10 ml per dose. Packaged as a 200 ml bottle with dosing syringe, it is designed for sublingual or oral administration. The formulation is optimized for neuroinflammatory support.
Composition
- Palmitoylethanolamide (ultramicronized form) – 700 mg per 10 ml
- Luteolin (ultramicronized) – 70 mg per 10 ml
- Excipients: water, corn dextrin, microcrystalline cellulose, sodium carboxymethylcellulose, polysorbate 80, potassium sorbate, citric acid
Pharmacological Action
This co‑ultramicronized formulation (PEALUT®) enhances absorption and bioavailability. PEA is an endogenous lipid mediator that modulates microglia, mast cells, and astrocytes, restoring neuro-glial homeostasis by reducing neuroinflammation, oxidative stress, and peripheral sensitization. Luteolin adds strong antioxidant and anti-inflammatory support, stabilizing mast cells and inhibiting NF‑κB and MAPK pathways.
Indications
Glialia 700 is indicated as a supportive treatment in:
- Neurological-inflammatory disorders such as post-stroke, mild cognitive decline, Parkinson’s, early neurodegeneration
- Post-traumatic brain injury or transient ischemic attacks
- Neuroinflammation-associated mood disorders or post-viral syndromes
- Chronic neuropathic pain, fibromyalgia, or persistent brain fog (e.g., post-COVID‑19)
Dosage and Administration
Typical dosing is 10 ml (one syringe) administered sublingually or orally 1–2 times daily for 20–30 days, potentially extendable to several cycles based on clinical response. Shake bottle before use. Suitable for use via nasogastric or PEG in cases of dysphagia.
Side Effects
- Occasional mild gastrointestinal discomfort (e.g., bloating)
- Rare headache or fatigue
- Possible mild skin reactions in sensitive individuals
Contraindications
- Pregnancy and breastfeeding—insufficient safety data
- Known hypersensitivity to PEA, luteolin, or formulation ingredients
Precautions
- Use under medical supervision—especially in patients with severe hepatic or renal impairment
- Monitor for potential interactions with immune-modulating therapies
Interactions
May interact with antiplatelet or anticoagulant medications. Patients taking warfarin or similar agents should monitor coagulation status. May influence results of cytokine or inflammatory biomarker assays.
Overdose and Treatment
No specific overdose cases reported. Excessive intake may lead to nausea or gastrointestinal discomfort. Cease administration and provide supportive care as needed.
Storage
- Store at room temperature (15–25 °C), protected from light and humidity
- Retain bottle tightly closed; use within expiration date
- Keep out of reach of children
Mechanism of Action
PEA binds PPAR‑α and exerts anti-nociceptive and anti-inflammatory effects, reducing mast cell degranulation and microglial activation. Luteolin enhances neuronal resilience by inhibiting inflammatory transcription factors and promoting antioxidant defenses. Together, PEA and luteolin restore neuroglial balance and support neuroprotection and synaptic stability.
Clinical Studies and Evidence
A randomized controlled trial in patients with long‑COVID-related cognitive symptoms showed that oral administration of Glialia® (ultramicronized PEA‑Luteolin, 700 mg + 70 mg daily) significantly improved measures of cortical excitability (LICI) and cognitive function compared to placebo. Versace et al., PMC 2022
A systematic review and meta-analysis published in Biomolecules (2023) confirmed that CoUltraPEALut improves recovery of olfactory function in post-COVID olfactory dysfunction (PCOD), with better TDI score outcomes when combined with olfactory training versus training alone. Capra et al., 2023
Use in Special Populations and Sports
Athletes and individuals subject to high cognitive or physical stress may benefit from Glialia’s anti-inflammatory and adaptogenic effects, including faster recovery, reduced fatigue, and improved mental clarity. Although not on WADA prohibited list, use in competitive settings should be managed by sports medicine professionals due to potential immunomodulatory and biomarker interactions.
Additional Notes
Co-ultramicronized PEA and luteolin (PEALUT®) allow for enhanced bioavailability and clinical efficacy at lower doses compared to non-ultramicronized forms. Use in elderly or frail patients may aid resilience and support quality of life, particularly in cognitive decline and sensory dysfunction.
Summary
Glialia 700 is an evidence-based neuronal support formulation combining palmitoylethanolamide and luteolin in an ultramicronized delivery form. It addresses neuroinflammation, oxidative stress, and neuronal dysfunction common to various CNS-related conditions. Supported by clinical trials in post-COVID cognitive and olfactory recovery, it offers a well-tolerated adjunct in neurological support under medical supervision.
Reviews
There are no reviews yet.